Mark Krystal
Mark Krystal has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
C. Cianci
Departments of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationChristopher Cianci
Department of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
1 shared publicationH. Putz
Departments of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publicationM. Hagen
Departments of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publication- Nicholas A. Meanwell
The Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States
1 shared publication R. J. Colonno
Departments of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
1 shared publication
Latest Publications
- 1 July 1997
- Published by Elsevier in Virus Research
- Vol. 50 (1) , 65-75
Differential effect of modified capped RNA substrates on influenza virus transcription
- 1 July 1997
- Published by Elsevier in Virus Research
- Vol. 50 (1) , 65-75
Differential effect of modified capped RNA substrates on influenza virus transcription
- 1 December 1996
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 7 (6) , 353-360
Identification of N-Hydroxamic Acid and N-Hydroxyimide Compounds that Inhibit the Influenza Virus Polymerase
The RNA-dependent RNA polymerase of influenza virus transcribes messenger RNA through a unique cap-scavenging mechanism. The polymerase binds to the cap structure at the 5′ ends of host mRNAs, which are then cleaved and used as primers for viral mRNA synthesis. In an effort to discover antiviral compounds against this target, an in-vitro transcription assay was utilized to screen a proprietary chemical collection. Results of this screening effort identified an N-hydroxamic acid structure as an inhibitor of the capped RNA-dependent transcriptase activity. Subsequent sub-structure searching and screening based upon this pharmacophore identified two related N-hydroxyimide compounds as specific inhibitors. These compounds were found to inhibit the cap-scavenging mechanism through inhibition of the endonuclease function of the polymerase.
- 1 December 1996
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 7 (6) , 353-360
Identification of N-Hydroxamic Acid and N-Hydroxyimide Compounds that Inhibit the Influenza Virus Polymerase
The RNA-dependent RNA polymerase of influenza virus transcribes messenger RNA through a unique cap-scavenging mechanism. The polymerase binds to the cap structure at the 5′ ends of host mRNAs, which are then cleaved and used as primers for viral mRNA synthesis. In an effort to discover antiviral compounds against this target, an in-vitro transcription assay was utilized to screen a proprietary chemical collection. Results of this screening effort identified an N-hydroxamic acid structure as an inhibitor of the capped RNA-dependent transcriptase activity. Subsequent sub-structure searching and screening based upon this pharmacophore identified two related N-hydroxyimide compounds as specific inhibitors. These compounds were found to inhibit the cap-scavenging mechanism through inhibition of the endonuclease function of the polymerase.